Notícias Fortress Biotech Inc - FBIO | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Fortress Biotech Inc (FBIO)
Fortress Biotech Inc (FBIO) Notícias

Fortress Biotech Inc (FBIO)

1,67

0,05

(3,09%)

No fechamento: 14 Março 5:00PM

Atrasado por 15 minutos

1,67

0,00

( 0,00% )

Após o horário de negociação: 5:30PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma

Sun Pharma to Acquire Checkpoint Therapeutics

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Mustang Bio Announces Reverse Stock Split

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Fortress Biotech

Societe Generale Effekten

BNP Paribas Issuance

Shift Technologies

BNP Paribas Issuance

Fintech Ecosystem Develo...

Fidelity Advisor Equity ...

DJ Commodity Index Grain...

Pentagon I Capital

Narrative Token

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições